Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
HRK Factory Erlotinib hydrochloride Raw Materials Powder on sale
Product Overview:
Erlotinib hydrochloride is the hydrochloride of the molecularly targeted drug Erlotinib, and the U.S. Food and Drug Administration (FDA) has approved Erlotinib (Tarceva) in combination with gemcitabine as a first-line treatment for locally advanced and metastatic pancreatic cancer.
The small-molecule compound erlotinib is a receptor tyrosine kinase inhibitor. By competitively binding the intracellular catalytic site of receptor tyrosine kinase with adenosine triphosphate in the cell, the phosphorylation reaction is inhibited, thus blocking the downward proliferation signal transmission and inhibiting the activity of ligand-dependent HER-1/EGFR in tumor cells, thus inhibiting the proliferation of tumor cells. Erlotinib is another tyrosine kinase inhibitor used in the treatment of NSCLC. The results of the Phase I clinical trial showed that the main toxicity and side effects were dose-dependent rash and diarrhea, and other rare side effects were headache, nausea and vomiting.
HRK Factory Erlotinib hydrochloride Raw Materials Powder on sale Attributes
CAS:183319-69-9
MF:C22H24ClN3O4
MW:429.9
EINECS:620-491-0
Specification: 99% min Erlotinib hydrochloride Powder
Sample:Erlotinib hydrochloride Powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
HRK Factory Erlotinib hydrochloride Raw Materials Powder on sale Details
Erlotinib hydrochloride Usage and Function.
Erlotinib targets the epidermal growth factor receptor subtype (EGFR-TK) that reversibly and selectively acts on tyrosine kinase receptors. Its mechanism of action is to compete with substrates in the cell, inhibit EGFR-TK phosphorylation, block the signaling of tumor cells, inhibit the growth of tumor cells, and induce their apoptosis. Clinical studies have shown that the drug has an inhibitory effect on a variety of tumors. Compared with traditional chemotherapy drugs, it has the advantages of less adverse reactions, better safety and tolerance.
Uses of Erlotinib hydrochloride.
Erlotinib hydrochloride is a small molecule epidermal growth factor receptor tyrosine kinase reversible inhibitor, mainly used in the treatment of locally advanced or metastatic non-small cell lung cancer second or third line treatment and pancreatic cancer.
In vitro study of Erlotinib hydrochloride.
Erlotinib inhibits EGFR autophosphorylation by acting on HNS human head and neck tumor cells, which are cell lines that express high levels of EGFR. Erlotinib had no effect on SBC-5 cell proliferation. In contrast, Erlotinib significantly inhibited the proliferation of PC-9 cells in a dose-dependent manner, and PC-9 cells contained deletion mutations in exon 19 of the EGFR gene. The Erlotinib treatment also did not affect SBC-5 cell migration. Erlotinib inhibited HPAC and Capan-1 cell growth with IC50 of 1.1 and 3µM, respectively. 10 uM Erlotinib inhibits EGFR phosphorylation at Y845 (SRc-dependent phosphorylation) and Y1068(autophosphorylation) sites. Erlotinib acts only on the most sensitive cell lines when it inhibits extracellular signal-regulating kinases, Akt, and S6.
Product Method of Bulk Erlotinib hydrochloride Powder.
